Introduction
Many reports have documented a role of insulin as well as of insulin growth factor type 1 (IGF-1) as growth factors in a variety of cancers. 1 Insulin and IGF-1 and their receptors are closely related molecules. A role of insulin has not been investigated carefully in multiple myeloma (MM), a clonal B-cell neoplasia characterized by the accumulation of malignant plasma cells (MMCs) within the bone marrow. In a study published in 1993, a high insulin concentration (400-fold higher than the physiological concentrations) was reported to increase slightly the proliferation of one myeloma cell line. 2 A role of insulin could be of importance as IGF-1 is the most important of the plethora of myeloma cell growth factors (MGFs) that has been described. 3 In particular, the MGF activity of interleukin-6 (IL-6), HB-EGF (heparin-binding epidermal growth factor) or hepatocyte growth factor is partly dependant on an IGF-1/IGF-1R loop. 4 IGF-1R is only expressed by the MMCs, unlike normal plasma cells, and patients with IGF-1R present MMCs had a significantly shorter survival than patients with IGF-1R absent MMCs. [4] [5] [6] Insulin and IGF-1 receptors share 60% overall amino acid sequence homology and 84% homology in their tyrosine kinase domains. 7 They are tetrameric glycoproteins composed of two extracellular a-subunits and two transmembrane b-subunits linked by disulfide bonds. 7 The a-and b-subunits are encoded by a single gene, whose gene product is glycosylated, proteolytically cleaved and crosslinked by cysteine bonds to form a functional transmembrane ab chain. The extracellular a-chain is involved in ligand binding and the intracellular b-chain includes the tyrosine kinase domain. 1 IGF-1, IGF-2 and insulinFthe ligands of these receptorsFhave also high sequence and structure similarity. This high sequence and structural homology between the receptors and between their ligands result in cross-talks between IGF-1 and insulin signaling. IGF-1 receptor (IGF-1R) and insulin receptor (INSR) can heterodimerize leading to the formation of insulin/IGF-1 hybrid receptors (hybrid-Rs), which comprises one a-and one b-subunit of each receptor. 8 
INSR exists in two isoforms, which differ by exon 11 splicingFINSR-A (INSR

Àex11
) and INSR-B (INSR þ ex11 )Fyielding to two possible hybrid-Rs: hybrid-R A and hybrid-R B . The ligands of these hybrid-Rs are controversially discussed. Whereas IGF-1 and IGF-2 can bind with high affinity to IGF-1R only and insulin to INSR only, Pandini et al. 8 have shown that IGF-1, IGF-2 and insulin may bind to hybrid-R A (IGF-1R/INSR-A) with high affinity. Only IGF-1 can bind to hybrid-R B with a high affinity, IGF-2 with a weaker affinity and insulin insignificantly. 8 Contrarily to these data, Slaaby et al. 9 found that these two hybrid-Rs have similar binding properties as the IGF-1R homodimer. They can bind IGF-1 and IGF-2 with high affinity and insulin with a very low affinity. Thus, the biological role of the hybrid-R is still unclear. Although they share strong homologies, the homodimeric receptorsFIGF-1R and INSRFhave different functions: IGF-1R signaling is predominantly involved in cell growth regulation, whereas INSR signaling controls carbohydrate metabolism regulation. 1 In this study, we have shown that insulin has a similar effect as IGF-1: insulin is an antiapoptotic and proliferation factor for myeloma cells. The mechanism of action likewise includes AKT and mitogen-activated protein kinase (MAPK) phosphorylations. The growth factor activity of insulin necessitates an activation of IGF-1R. Only INSR þ IGF-1R þ myeloma cell lines can be stimulated by insulin, unlike INSR þ IGF-1R À myeloma cell lines. In agreement, the insulin growth activity is inhibited by not only an anti-INSR monoclonal antibody (mAb) but also by an IGF-1R kinase inhibitor or an anti-IGF1R mAb. We show the presence of INSR/IGF-1R heterodimers at the cell surface of human myeloma cell lines (HMCLs) and that insulin induces both IGF-1R and INSR phosphorylations. This MGF activity of insulin through insulin/IGF-1 hybrid-Rs is of importance for the development of strategies aiming at the neutralization of MMC survival and proliferation triggered by IGF-1R activation in MMC.
Materials and methods
Cell samples
The 14 HMCLs were obtained in our laboratory (XG HMCLs), 10 provided by Dr Pellat-Deceunynck (BCN, Nantes, France) or purchased from ATCC (NCI-H929, LP-1, OPM2, L363; Rockville, MD, USA). They were maintained in RPMI-1640 (Invitrogen, Carlsbad, CA, USA), 10% fetal bovine serum (PAA laboratory GmbH, Linz, Austria) and, for the IL-6-dependant cell lines, with 2 ng/ml of IL-6. CD27
þ memory B cells, in vitro generated polyclonal plasmablasts (day 7 plasmablasts, CD20
À cells) and plasma cells (day 10 plasma cells, CD20 À CD38 þ þ CD138 À cells) were obtained as previously described. 11 Normal bone marrow plasma cells and MMCs of 206 patients with previously untreated MM were purified as described. 12 These patients presenting with previously untreated MM (n ¼ 206) at the University Hospitals of Heidelberg and Montpellier and the healthy normal donors were included in the studies approved by the institutional review board of the Medical Faculty of the Ruprecht-Karls-University Heidelberg, Germany, and the institutional review board of the CHU Montpellier, France, for the respective patients. Written informed consent was obtained in accordance with the Declaration of Helsinki. These 206 patients were treated with high-dose therapy and autologous stem cell transplantation and were termed in the following Heidelberg-Montpellier (HM) series. Bone marrow of patients with MM was obtained for routine follow-up and excess cells were used with written consent of the patients.
Reagents
Recombinant human IL-6 was purchased from Abcys SA (Paris, France), recombinant human IGF-1 from R&D Systems (Minneapolis, MN, USA), and recombinant human insulin from Roche Diagnostics (Basel, Switzerland). The B-E8 anti-IL6 mAb was a generous gift from Dr Wijdenes (Diaclone, Besancon, France) 13 and the NVP-AEW541 IGF-1R inhibitor was from Novartis Pharma AG (Basel, Switzerland).
14 The anti-INSR antibody was purchased from Abcam (Cambridge, UK) and the aIR3 anti-IGF-1R mAb from Calbiochem (Darmstadt, Germany). The Syn-H Iscove-based fully defined culture medium containing human albumin, antioxidative reagents and amino acids without insulin was purchased from ABCellBio (Montpellier, France). Small interfering RNAs (siRNAs) to INSR (siINSR), IGF-1R (siIGF-1R) or 1 nM non-targeting siRNA (siGLO) were purchased from Dharmacon (Lafayette, CO, USA).
Flow cytometry analysis
The expression INSR on HMCLs was evaluated by incubating 5 Â 10 5 cells with phycoerythrin-conjugated anti-human INSR (BD Biosciences, San Diego, CA, USA) or an isotype-matched control antibody in phosphate-buffered saline containing 2% fetal bovine serum at 4 1C for 30 min. The cells were washed twice in phosphate-buffered saline. Flow cytometry analysis was performed on a FACScan (Becton Dickinson, San Jose, CA, USA). The mean fluorescence intensity obtained with the isotype-matched control antibody was set between 3 and 5.
Microarray hybridization
RNA was extracted with the RNeasy Kit (Qiagen, Valencia, CA, USA), the SV-total RNA extraction kit (Promega, Mannheim, Germany) and Trizol (Invitrogen, Karlsruhe, Germany) in accordance with the manufacturer's instructions. Biotinylated complementary RNA was amplified with a double in vitro transcription, according to the Affymetrix small sample labeling protocol (Affymetrix, Santa Clara, CA, USA). The biotinylated complementary RNA was fragmented and hybridized to human U133 2.0 GeneChip microarrays according to the manufacturer's instructions (Affymetrix). Fluorescence intensities were quantified and analyzed using the GECOS software (Affymetrix). Arrays were scaled to an average intensity of 100. A threshold of 1 was assigned to values o1.
Real-time reverse transcriptase-PCR
Total RNA was converted to complementary DNA using the Superscript II reverse transcriptase (Invitrogen, Cergy Pontoise, France). The assays-on-demand primers and probes and the TaqMan Universal Master Mix were used according to the manufacturer's instructions (Applied Biosystems, Courtaboeuf, France). Measurement of gene expression was performed using the ABI Prism 7000 Sequence Detection System. Quantitative PCR analysis was completed using ABI PRISM 7000 SDS Software. For each primer, serial dilutions of a standard complementary DNA were amplified to create a standard curve, and values of unknown samples were estimated relative to this standard curve in order to assess the PCR efficiency. Ct values were collected for GAPDH (glyceraldehyde 3-phosphate dehydrogenase) and the genes of interest during log phase of the cycle. The gene of interest levels were normalized to GAPDH for each sample (dCt ¼ Ct gene of interest-Ct GAPDH) and compared with the values obtained for a known positive control using the formula, 100/2 ddCt , where ddCt ¼ dCt unknown-dCt positive control.
Signal transduction and immunoblot analysis
To look for signal transduction, myeloma cell lines were harvested in the exponential growth phase. Cells were washed twice in RPMI/1% bovine serum albumin and starved at 37 1C for 18 h in the Syn-H serum-free culture medium. After two washings, cells (10 6 cells/ml) were incubated with pre-warmed insulin (100 ng/ml) or IGF-1 (100 ng/ml) with or without inhibitors for 20 min. In preliminary experiments, a 20-min stimulation made it possible to get an optimal triggering of transduction pathways by recombinant MGF. The IGF-1R kinase inhibitor or the anti-INSR mAb were added to the cells for 4 h at the end of starvation culture and during exposure to recombinant MGF. Cells were lysed in 10 mM Tris-HCl (pH 7.05), 50 mM NaCl, 50 mM NaF, 30 mM sodium pyrophosphate, 1% Triton X-100, 5 mM ZnCl 2 , 100 mM Na 3 VO4, 1 mM dithiothreitol, 20 mM b-glycerophosphate, 20 mM p-nitrophenol phosphate, 20 mg/ml aprotinin, 2.5 mg/ml leupeptin, 0.5 mM phenylmethylsulfonyl fluoride, 0.5 mM benzamidine, 5 mg/ml pepstatin and 50 nM okadaic acid. Lysates were resolved on 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane (Schleicher and Schuell, Kassel, Germany). Membranes were blocked for 2 h at room temperature in 140 mM NaCl, 3 mM KCl, 25 mM Tris-HCl (pH 7.4), 0.1% Tween 20 (tris-buffered saline Tween-20), 5% non-fat milk, and then immunoblotted with anti-phospho-Akt, anti-phospho-MAPK, anti-Akt and anti-MAPK antibodies (Cell Signaling Technology, Beverly, MA, USA). As a control for protein loading, we used a mouse monoclonal anti-b-actin antibody (Sigma, St Louis, MO, USA). The primary antibodies were visualized with goat anti-rabbit (Sigma) or goat anti-mouse (Bio-Rad, Hercules, CA, USA) peroxidase-conjugated antibodies by an enhanced chemiluminescence detection system.
Immunoprecipitation of insulin and IGF-1 receptors proteins
Before sodium dodecyl sulfate-polyacrylamide gel electrophoresis and western blot studies, the cells were solubilized with ice-cold cell lysis buffer (20 mM Tris, 150 mM NaCl, 5 mM EDTA, 0.5% sodium deoxycholate and 0.5% Triton X-100, pH 7.5) supplemented with protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1.5 mg/ml leupeptin and 1.5 mg/ml aprotinin) and a phosphotyrosine phosphatase inhibitor (1 mM sodium vanadate) for 30 min on ice. Cell lysates were scraped and further disrupted by passage through a syringe needle. The lysates were then centrifuged at 14 000 g for 15 min at 4 1C and the supernatants were collected. To immunoprecipitate INSR or IGF-1R, cell lysates (10 7 cells) were incubated with 2 mg anti-INSR or anti-IGF-1R antibodies overnight on a shaker at 4 1C. The day after, protein A/G plus-agarose (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was added to lysates and incubated on a rocker overnight at 4 1C to capture immunocomplexes. After three washes with ice-cold cell lysis buffer, the pellets of agarose-bound protein were resuspended in 50 ml of 2Â Laemmli sample buffer and were boiled for 2 min to dissociate the immunocomplexes from the beads and reduce the disulfide bridges holding the receptor subunits together.
To study monomeric receptors (denaturing conditions), cell lysate was treated with 1 mM dithiotreitol for 30 min at 4 1C to separate the receptor b-subunits from each other before immunoprecipitation (IP). The reduction was then terminated with 3 mM N-ethylmaleimide. 15 Lysates were resolved on 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane (Schleicher and Schuel). Membranes were blocked for 2 h at room temperature in tris-buffered saline Tween-20, 5% non-fat milk, and then immunoblotted with anti-phospho-IGF-1R/INSR (Cell Signaling Technology), anti-IGF-1R and anti-INSR antibodies (Santa Cruz).
Assay for myeloma cell line growth
HMCLs were IL-6-and serum-starved for 2 h and cultured for 4 days in 96-well flat-bottomed microtiter plates in Syn-H serum-free culture medium without cytokine (control) or with insulin or IGF-1, without or with the IGF-1R inhibitor NVP-AEW541 (0.5 mM) or the anti-INSR mAb (1 mg/ml). At the end of the culture, the number of viable cells was evaluated by quantifying intracellular ATP amount with a Cell Titer Glo Luminescent Assay (Promega Corporation, Madison, WI, USA) with a Centro LB 960 luminometer (Berthold Technology, Bad Wildbad, Germany).
Short-term culture of primary myeloma cells
A survival effect of recombinant insulin (100 ng/ml) or IGF-1 (100 ng/ml) on primary MMCs of patients was evaluated culturing bone marrow mononuclear cells of patients with MM for 5 days at 5 Â 10 5 cells/ml in Syn-H serum-free medium as reported previously. 16 At the end of the culture, viable cell numbers were determined using Trypan blue staining and the percentage of viable myeloma cells was assayed using labeling with an anti-CD138-phycoerythrin monoclonal antibody (Beckman-Coulter, Marseille, France) and fluorescenceactivated cell sorting (FACS) analysis. CD138 is expressed on viable MMCs only. 17 The role of insulin or IGF-1 present in AB serum to support primary MMC survival in short-term cultures was evaluated culturing bone marrow mononuclear cells from patients with MM in RPMI-1640 and 5% AB serum in the presence of a neutralizing anti-INSR mAb (1 mg/ml) or of IGF binding protein 3 (IGFBP-3; 2 mg/ml) as an IGF-1 inhibitor. At the end of the culture, the number of viable MMCs was determined as indicated above.
Statistical analysis
A difference in the mean values of two (paired) groups was evaluated with (paired) Student's t-test using the SPSS10 software (SPSS, Chicago, IL, USA). Gene Expression Profiles were analyzed with our RAGE bioinformatics platform (RAGE, (remote analysis of microarray gene expression) http://rage. montp.inserm.fr) designed by T Rème 18 and with the Amazonia website (amazonia.montp.inserm.fr). 19 The prognostic value of a probe set was evaluated using the Affymetrix call ('present' or 'absent') that is determined by the Affymetrix GCOS software as indicator whether a gene is expressed or not. The statistical significance of differences in survival between groups of patients was calculated by the log-rank test. An event was defined as relapse or disease progression (for event-free survival) or as death (for overall survival). Survival curves were plotted using the Kaplan-Meier method. 
Results
Expression of INSR in normal plasma cells, primary myeloma cells and myeloma cell lines
Myeloma growth factor activity of insulin
Insulin significantly stimulated the growth of 12 of 14 HMCLs, which expressed both IGF-1R and INSR (Pp0.05; Figure 2a ). The two HMCLs that were not stimulated by insulin were IGF-1R
À . The XG-10 HMCL did not express both IGF-1R and INSR, and XG-12 expressed INSR, unlike IGF-1R. The growth activity of insulin was observed with XG IL-6-dependant cell lines and commercially available cell lines (NCI-H929, LP-1, OPM2 and L363). It was already significant with 100 pg/ml insulin for the most sensitive HMCLs and increased with graded insulin concentrations. With 100 ng/ml insulin, the growth stimulation ranged from 2.1-fold (XG-20) to 18-fold (XG-2). As reported, 4 IGF-1 stimulated HMCLs (Pp0.05), unlike the IGF-1R
À HMCLs (XG-10 and XG-12). We show here additional data indicating that IGF-1 growth activity was already significant with 100 pg/ml IGF-1, as for insulin, and became higher with increasing IGF-1 concentrations (Figure 2b ). The growth stimulations were in the same range as those for insulin, that is, from 2.5-fold (XG-6) to 16-fold (XG-2). The four HMCLs for which growth was most effectively stimulated by insulin (that is, XG-2, XG-1, NCI-H929 and BCN) were also most strongly stimulated by IGF-1. No correlation between the fold stimulation by insulin or IGF-1 and INSR or IGF-1R gene or protein expressions was found.
Inhibition of insulin growth activity by INSR or IGF-1R inhibitors
The MGF activity of insulin was blocked by an anti-INSR mAb and this anti-INSR mAb did not affect the IGF-1 MGF activity. Data for four HMCLs (that is, XG-2, XG-5, XG-6 and XG-7) are shown in Figure 3 . The growth of XG-10 and XG-12 HMCLs, which were not stimulated by recombinant insulin or IGF-1, was , 5 samples of plasmablasts generated at day 7 using an in vitro model (D7 PBs), 11 5 samples of plasma cells generated at day 10 using an in vitro model (D10 PCs), 11 7 samples of purified bone marrow plasma cells (BMPCs), primary myeloma cells (MMCs) from 206 newly diagnosed patients with MM and 14 HMCLs. The top, bottom and middle lines of each box correspond to the 75th percentile (top quartile), 25th percentile (bottom quartile) and 50th percentile (median) of the Log 2 Affymetrix signal for INSR 226450_at probe set. The significance of the differences in median INSR gene expressions in the various populations was evaluated using Wilcoxon test. *Wilcoxon test was significant (Pp0.05).
not affected either by the anti-INSR mAb or IGF-1R inhibitor (Figures 3e and f) . Of note, the NVP-AEW541 IGF-1R kinase inhibitor also blocked insulin MGF activity, the efficacy depending on the cell line. This IGF-1R inhibitor fully blocked the MGF activity of IGF-1. The NVP-AEW541 IGF-1R inhibitor strongly suppressed the survival of some HMCLs, in particular XG-6, without adding exogenous MGF, indicating that an autocrine IGF-1/IGF-1R loop was functional as reported. (Table 1) . We also looked whether knocking out INSR expression using the siRNA pool to INSR could block insulin-induced growth. A pool of four siRNAs to INSR reduced INSR protein expression by 32% as assayed by western blot, whereas INSR was not affected by siRNAs to IGF-1R. The siRNA pool to IGF-1R reduced IGF-1R protein expression by 47% and, of note, the siRNA to INSR increased by 63% IGF-1R expression (Supplementary Figure  S1A) . The growth activity of insulin was decreased by a half by the siRNAs to INSR and that of IGF-1 was unaffected by siRNA to IGF-1R (Supplementary Figure S1B) .
Insulin supports myeloma cell survival and proliferation and phosphoinositol-3 kinase/AKT and MAP kinase activations
We investigated whether insulin is both a survival and proliferation factor for human myeloma cells. Without adding recombinant growth factors, the four HMCLs tested (XG-2, XG-7, XG-10 and XG-12) apoptosed within 3 days as assayed with annexin-V staining (Table 2a) . Insulin reduced the apoptosis rate of the two IGF-1R þ HMCLs (Pp0.05), but had no effect on INSR À IGF-1R À XG-10 and INSR þ IGF-1R À XG-12 HMCLs. In a control experiment, we showed that IGF-1 promoted the survival of the two IGF-1R þ HMCLs. IL-6 promoted the survival of all four tested HMCLs, independent of IGF-1R þ /À state. The proliferative activity of insulin was investigated with anti-5-bromodeoxyuridine labeling. Insulin stimulated the percentage of cells in the S phase of XG-2 and XG-7 cells (Pp0.05), unlike that of XG-10 and XG-12 HMCLs (Table 2b ). The proliferative effect of IGF-1 paralleled that of insulin. IL-6 stimulated the proliferation of all four tested HMCLs (Table 2b) .
Insulin induced the phosphorylation of AKT and MAPK (Figure 4a ) but did not activate Janus kinase/signal transducer and activator of transcription 3 or nuclear factor-kB pathways (result not shown). The anti-INSR mAb as well as the NVP-AEW541 IGF-1R inhibitor blocked the insulin-induced signal transduction (Figure 4a ). The NVP-AEW541 IGF-1R inhibitor and the IR3a anti-IGF-1R mAb used are known to be specific of
IGF-1R and do not recognize INSR. In our hands, they do not block AKT and MAPK phosphorylations induced by insulin in the IGF-1R
À XG-12 cell line, unlike the anti-INSR mAb. We have recently shown that IGF-1 also activates AKT and MAPK phosphorylations in myeloma cells, unlike signal transducer and activator of transcription 3 or nuclear factor-kB. 4 In several experiments, the NVP-AEW541 IGF-1R inhibitor was more efficient in inhibiting AKT and MAPK phosphorylations in XG-2 cells 20 min after insulin activation than the anti-INSR mAb. An explanation is that the IGF-1R inhibitor is a direct IGF-1R kinase inhibitor, likely being more efficient in blocking the 20-min AKT and MAPK phosphorylations than the anti-INSR mAb.
Insulin receptors associate with IGF-1R at the cell membrane of myeloma cells
Using western blot analysis, both INSR and IGF-1R were detected in the INSR þ IGF-1R þ XG-7 HMCL (Figure 4b ). Abbreviations: BrdU, 5-bromodeoxyuridine; HMCL, human myeloma cell line; IGF-1, insulin growth factor type 1; IL-6, interleukin-6. HMCLs were starved for 2 h and cultured without growth factor (control) or with insulin (10 ng/ml), IGF-1 (10 ng/ml) or IL-6 (2 ng/ml) for 3 days in the Syn-H culture medium. The starting cell concentration was 2 Â 
Insulin induced IGF-1R phosphorylation
As the MGF activity of insulin is inhibited by the mAb to IGF-1R and INSR is associated with IGF-1R in myeloma cells, we have investigated whether insulin can induce IGF-1R phosphorylation. As there is no relevant antibody that is specific to phosphorylated IGF-1R only, we took advantage of the ability to immunoprecipitate INSR and/or IGF-1R in non-denaturating or denaturating conditions as shown in Figure 4b 
Myeloma cell growth activity of serum insulin
We have investigated whether circulating insulin present in human AB serum could be partly responsible for the myeloma cell growth activity of serum. Adding increasing concentrations of human AB serum increased the growth of myeloma cells (Figure 5a ). The reported concentration of insulin in human serum is about 2 ng/ml and that of IGF-1 and IGF-2 are 100-200 ng/ml. 1 An anti-INSR mAb (1 mg/ml) significantly reduced (Po0.05) the serum-induced myeloma cell growth activity. This anti-INSR mAb (1 mg/ml) completely blocked the insulin growth activity (10 ng/ml), without affecting that of 10 ng/ml IGF-1 (Figure 5b ). Blocking IGF-1 activity with recombinant IGFBP-3 (2 mg/ml) also reduced the serum-induced growth. Recombinant IGFBP-3 (2 mg/ml) completely blocked the myeloma cell growth activity of 10 ng/ml IGF-1, without affecting that of 10 ng/ml insulin (Figure 5b ). Of interest, adding both the anti-INSR mAb and IGFBP-3 synergistically inhibited myeloma cell growth induced by human serum (Figure 5a ). Insulin is a growth factor for human multiple myeloma cells AC Sprynski et al Insulin can promote the survival of primary myeloma cells
To evaluate the role of insulin on the survival of patients' primary MMCs, two culture systems were used. First, bone marrow mononuclear cells from patients with MM (containing primary MMCs and other bone marrow cells) were cultured for 5 days in serum-free culture medium. Viable MMCs were assayed using FACS staining of membrane CD138 as early apoptotic MMCs rapidly loss membrane CD138. 17 As illustrated in Figure 5c for one patient sample, MMCs did not survive in serum-free culture, and addition of recombinant insulin or of recombinant IGF-1 conferred survival on MMCs. Similar data were observed for the bone marrow samples of other six patients (Table 3 ). This survival effect of insulin or IGF-1 was observed only with primary MMCs that expressed IGF-1R. In the second culture system, bone marrow mononuclear cells were cultured with RPMI-1640 and 5% human AB serum. The neutralizing anti-INSR mAb could significantly reduce the AB serum effect (P ¼ 0.018, Figure 5c and Table 3 ). The IGFBP-3 inhibitor to IGF-1 was more efficient in blocking AB serum survival effect, but this is hardly surprising as serum IGF-1 concentration is 100-fold higher than that of insulin ( Figure 5c and Table 3 ).
Discussion
This is the first report showing that insulin is a potent growth and survival factor for human myeloma cell lines and for primary MMCs. The growth activity started to be detectable with a concentration of 100 pg/ml insulin, a concentration 30-fold below physiological concentrations. 1 The insulin MGF activity increased with insulin concentrations, as does the MGF activity The anti-INSR mAb (1 mg/ml) specifically blocked the effect of insulin (10 ng/ml) unlike that of IGF-1 (10 ng/ml) and IGFBP-3 (2 mg/ml), and of IGF-1 (10 ng/ml) unlike that of insulin (10 ng/ml). *The mean value was significantly different from that obtained in the control group using Student's t-test (Pp0.05); **the mean luminescent signal with insulin and anti-INSR mAb (IGF-1 and IGFBP-3) was significantly lower than that with insulin (IGF-1) (Pp0.05); ***the mean luminescent signal with insulin and IGFBP-3 (IGF-1 and anti-INSR mAb) was not significantly different than that with IGF-1 (insulin). (c) Bone marrow mononuclear cells (5 Â 10 5 cells/ml) from patients with MM were cultured for 5 days in two culture systems. The first one used Syn-H serum-free culture medium without or with 100 ng/ml recombinant insulin or IGF-1. The second one used RPMI-1640 þ 5% AB serum without or with neutralizing anti-INSR mAb (1 mg/ml) or IGFBP-3 (2 mg/ml). At the end of the culture, viable cells were counted and the MMCs expressing CD138 were determined. Data are dot plot FACS profiles of CD138 labeling and side scatter (SSC) of one patient sample representative of seven.
of IGF-1, both in terms of bioactive concentrations and extent of growth induction. The insulin MGF activity requires both INSR and IGF-1R because it is observed only in IGF-1R þ HMCLs and is abrogated by IGF-1R or INSR inhibitors. On the contrary, the IGF-1 MGF activity is not affected by an anti-INSR neutralizing mAb, but fully blocked by IGF-1R inhibitors. Human plasma comprises about 2 ng/ml insulin and 100-200 ng/ml IGF-1 and IGF-1 bound to IGFBP, mainly IGFBP-3 and acid-labile subunit. 1 In this study we have shown that the insulin activity present in human serum is responsible, in part, of the myeloma cell growth activity of human serum. This was observed with both HMCLs and primary MMCs.
There was no correlation between the FACS-based INSR concentration and the extent of proliferative effect of insulin in HMCLs. We and others have previously found that there was also no correlation between IL-6 proliferative effect and IL-6R and gp130 IL-6 transducer expressions. A likely explanation is that the HMCLs have abnormalities targeting the intracellular signaling pathways, in particular the nuclear factor-kB pathway, [20] [21] [22] the ras pathway and myc pathway with myc translocations occurring in virtually all HMCLs. 23 Additional abnormalities involve the AKT pathway, in particular a loss of phosphatase and tensin homolog. 24 In addition, several HMCLs produce autocrine IGF-1 that will confer an autocrine IGF-1R activation, reducing the effect of adding exogenous insulin. 4 These data further extend the importance of insulin as a growth factor in epithelial cancers, that is, breast, prostate, colon and pancreatic, in part signaling through hybrid-Rs. 1 In these cancers, INSR is overexpressed in tumor cells compared with normal cells. 25 The surexpression of INSR promotes the formation of hybrid-Rs and the number of functional receptors for IGF-1FIGF-1R and hybrid-RsFthat have the same affinity for IGF-1. 26 In breast cancer lines, Pandini et al. 27 have shown hybrid-Rs to be the most abundant form of receptors at the cell surface of tumor cells compared with IGF-1R or INSR homodimers. Challenging results have been reported regarding the ability of hybrid-Rs to bind insulin with high affinity. Pandini et al. 27 found insulin to be able to bind the hybrid-Rs with high affinity, whereas Slaaby et al. 9 found that IGF-1 had at least a 50-fold higher affinity compared with insulin. Our current data are in favor of a high affinity of insulin to bind and to activate hybrid-Rs in myeloma cells. Indeed, the insulin concentrations triggering myeloma cell growth were similar to those of IGF-1, and in particular, the biological activity of insulin could be detected at low concentrations (100 pg/ml). It has been shown that the dimers involving two molecules of either IGF-1R, INSR or IGF-1R and INSR are preformed before ligand activation. 7 It is noteworthy that both anti-INSR mAb or IGF-1R inhibitor blocked the effect of insulin, whereas only IGF-1R inhibitor blocked the effect of IGF-1, unlike anti-INSR. This suggests that the preformed IGF-1R dimers are at sufficient concentrations to yield an optimal proliferative activity of IGF-1 or that the anti-INSR mAb does not affect the binding of IGF-1 to the hybrid-Rs as previously noted. 28 In this study we show that INSR is a plasma cell marker. INSR gene was not expressed by normal memory B cells (absent Affymetrix call), but was induced upon in vitro differentiation of memory B cells into day 4 activated B cells, day 7 plasmablasts and then day 10 plasma cells.
11 INSR was also highly expressed in normal bone marrow plasma cells. The Affymetrix data were confirmed by real time reverse transcriptase-PCR and FACS analysis (results not shown). There might be an interesting role of insulin in normal plasma cell differentiation, function and survival. The main biological function of plasma cells is to secrete high amounts of immunoglobulin, necessitating high uptake of amino acids. Plasma cell differentiation is also associated with the expression of a high density of syndecan-1, with the necessity to continuously synthesize large levels of heparan sulfate chains and to import glucose. 29 In mammalian were cultured for 5 days at 5 Â 10 5 cells/ml in serum-medium free without cytokine or with either insulin (100 ng/ml) or IGF-1 (100 ng/ml). To study the role of human serum insulin or IGF-1, primary myeloma cells were cultured in RPMI-1640 medium and 5% AB serum with either the anti-INSR mAb (1 mg/ml) or IGFBP-3 (2 mg/ml). In each culture group, cells were counted and labeled with an anti-CD138-PE antibody and CD138 + and CD138
À cells determined by FACS analysis. Data are the median values and ranges determined of seven patients' samples. Results in bold indicate that the median value compared with that of the control group is statistically significantly different using a Wilcoxon test for pairs (Pp005).
cells, these metabolic functions are upregulated by insulinmediated INSR activation. 30 INSR is also expressed in primary MMCs at the same level as that found in normal bone marrow plasma cells. But a major difference between normal and malignant plasma cells is that normal plasmablasts or plasma cells do not express IGF-1R. 4 In a previous work, we found that IGF-1R gene is expressed in 35 and 50% of primary myeloma cells in two large series of newly diagnosed patients, in association with a poor prognosis, 4 confirming previous data with a small cohort of 37 patients studied with flow cytometry. 5 This aberrant expression of IGF-1R in MMCs is likely a key oncogenic event in MM. It would be important to elucidate which mechanisms control this aberrant IGF-1R expression in MMCs and why insulin requires IGF-1R to trigger MMC growth. A difference in insulin and IGF-1 biological activities while activating common signaling pathways is a current finding in various cell lineages, and may involve three critical nodes, the insulin receptor substrate proteins, the recruited phosphoinositol-3 kinase subunits and then AKT isoforms. 30 We have shown that insulin can trigger INSR, AKT and MAPK phosphorylations in the INSR þ IGF-1R À XG-12 HMCLs without triggering myeloma cell growth (results not shown) and this model will be promising to further elucidate insulin receptor substrate proteins, PI-K subunits and AKT isoforms involved.
In vivo, the aberrant expression of IGF-1R in primary MMCs forming hybrid receptor with INSR could have two consequences. First, it will increase the number of high-affinity receptor for IGF-1 and IGF-2, both as IGF-1R homodimers and hybrid-Rs. The availability for IGF receptor on MMCs is likely the major limitation for IGF MGF activity, as IGF-1 or IGF-2 are not limiting in the myeloma milieu in vivo: (1) myeloma cells themselves and the tumor environment, in particular osteoclasts, produce IGF-1 31 and (2) IGF-1 and IGF-2 circulate at high levels (20-90 nM, that is, 150-700 ng/ml), bound to IGF-binding proteins, mainly in the form of an IGF/IGFBP-3/acid-labile subunit trimer. The availability of circulating IGF to tissue involves a close regulation of IGFBP as demonstrated in several models. 26 The second consequence is to confer MGF activity to physiological concentrations of insulin. Contrary to IGF-1, no circulating insulin binding (inhibitory) molecules exist, making insulin more easily available for cell surface receptors. A direct role of insulin in cancer progression was shown in several studies. Obesity is associated with an increased risk of cancer, in particular of MM, in humans. 32 Plasma c-peptide levels, reflecting insulin secretion, are associated with prostate specific death in men. 33 There is also a relationship between high-fasting insulin levels and risk of relapse in breast cancers. 34 It would be of interest to investigate a possible link between hyperinsulinemia-related markers and clinical and survival outcome in patients with MM. In particular, an increased risk for MM is found in patients with type II diabetes 35 as that was found for risk of overall cancers. 36 The current observation that insulin is a potent myeloma cell growth factor, signaling through hybrid-Rs, is of importance in several ways: (1) for the development of therapies targeting the IGF axis in patients with MM. Here, it will be needed to be taken into account that the anti-IGF-1R inhibitors block the hybrid receptor activated by both IGF-1 and IGF-2 and also insulin; (2) treatments blocking noctural glyconeogenesis (that is, reducing hyperinsulinemia) or metabolic activation as metformin, which have been shown to be of interest in cancer, 1 might be an additional treatment option in myeloma as well; (3) in patients with MM and type II diabetes, compounds further increasing the insulin level, for example, sulfonyl-urea derivatives like Glibenclamid, might be warranted to be avoided where possible.
